165 related articles for article (PubMed ID: 36714356)
1. Neoadjuvant Chemotherapy for Breast Cancer: Evolution of Clinical Practice in a French Cancer Center Over 16 Years and Pathologic Response Rates According to Tumor Subtypes and Clinical Tumor Size: Retrospective Cohort Study.
Houvenaeghel G; de Nonneville A; Cohen M; Viret F; Rua S; Sabiani L; Buttarelli M; Charaffe E; Monneur A; Jalaguier-Coudray A; Bannier M; Sabatier R; Gonçalves A
J Surg Res (Houst); 2022; 5(3):511-525. PubMed ID: 36714356
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemotherapy for breast cancer: Pathologic response rates but not tumor size, has an independent prognostic impact on survival.
Houvenaeghel G; de Nonneville A; Cohen M; Sabiani L; Buttarelli M; Charaffe E; Jalaguier A; Bannier M; Tallet A; Viret F; Gonçalves A
Cancer Med; 2024 Feb; 13(3):e6930. PubMed ID: 38327130
[TBL] [Abstract][Full Text] [Related]
3. Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy.
Barron AU; Hoskin TL; Day CN; Hwang ES; Kuerer HM; Boughey JC
JAMA Surg; 2018 Dec; 153(12):1120-1126. PubMed ID: 30193375
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
[TBL] [Abstract][Full Text] [Related]
5. Association of Tumor Molecular Subtype and Stage with Breast and Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer.
Myers SP; Ahrendt GM; Lee JS; Steiman JG; Soran A; Johnson RR; McAuliffe PF; Diego EJ
Ann Surg Oncol; 2021 Dec; 28(13):8636-8642. PubMed ID: 34142288
[TBL] [Abstract][Full Text] [Related]
6. Association of higher axillary pathologic complete response rate with breast pathologic complete response after neoadjuvant chemotherapy.
Zhu J; Li J; Fan Z; Wang H; Zhang J; Yin Y; Fu P; Geng C; Jin F; Jiang Z; Liu Z
Ann Transl Med; 2020 Aug; 8(16):992. PubMed ID: 32953792
[TBL] [Abstract][Full Text] [Related]
7. Impact of Neoadjuvant Chemotherapy on Nodal Disease and Nodal Surgery by Tumor Subtype.
Al-Hilli Z; Hoskin TL; Day CN; Habermann EB; Boughey JC
Ann Surg Oncol; 2018 Feb; 25(2):482-493. PubMed ID: 29181679
[TBL] [Abstract][Full Text] [Related]
8. Neo-adjuvant chemotherapy and axillary de-escalation management for patients with clinically node-negative breast cancer.
Shi ZQ; Qiu PF; Liu YB; Cong BB; Zhao T; Chen P; Wang CJ; Zhang ZP; Sun X; Wang YS
Breast J; 2019 Nov; 25(6):1154-1159. PubMed ID: 31332886
[TBL] [Abstract][Full Text] [Related]
9. Association between tumor molecular subtype, clinical stage and axillary pathological response in breast cancer patients undergoing complete pathological remission after neoadjuvant chemotherapy: potential implications for de-escalation of axillary surgery.
Hong J; Tong Y; He J; Chen X; Shen K
Ther Adv Med Oncol; 2021; 13():1758835921996673. PubMed ID: 33737963
[TBL] [Abstract][Full Text] [Related]
10. The diagnostic accuracy of magnetic resonance imaging in predicting pathologic complete response after neoadjuvant chemotherapy in patients with different molecular subtypes of breast cancer.
Zhang X; Wang D; Liu Z; Wang Z; Li Q; Xu H; Zhang B; Liu T; Jin F
Quant Imaging Med Surg; 2020 Jan; 10(1):197-210. PubMed ID: 31956542
[TBL] [Abstract][Full Text] [Related]
11. Axillary Downstaging in Occult Primary Breast Cancer After Neoadjuvant Chemotherapy.
Botty Van den Bruele A; Lavery J; Plitas G; Pilewskie ML
Ann Surg Oncol; 2021 Feb; 28(2):968-974. PubMed ID: 32813202
[TBL] [Abstract][Full Text] [Related]
12. Relationship Between Breast and Axillary Pathologic Complete Response According to Clinical Nodal Stage: A Nationwide Study From Korean Breast Cancer Society.
Ryu JM; Choi HJ; Park EH; Kim JY; Lee YJ; Park S; Lee J; Park HK; Nam SJ; Kim SW; Lee JH; Lee JE;
J Breast Cancer; 2022 Apr; 25(2):94-105. PubMed ID: 35506578
[TBL] [Abstract][Full Text] [Related]
13. Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy-A Rare Event.
Barrio AV; Montagna G; Mamtani A; Sevilimedu V; Edelweiss M; Capko D; Cody HS; El-Tamer M; Gemignani ML; Heerdt A; Kirstein L; Moo TA; Pilewskie M; Plitas G; Sacchini V; Sclafani L; Tadros A; Van Zee KJ; Morrow M
JAMA Oncol; 2021 Dec; 7(12):1851-1855. PubMed ID: 34617979
[TBL] [Abstract][Full Text] [Related]
14. Correlation Between Pathologic Complete Response in the Breast and Absence of Axillary Lymph Node Metastases After Neoadjuvant Systemic Therapy.
Samiei S; van Nijnatten TJA; de Munck L; Keymeulen KBMI; Simons JM; Kooreman LFS; Siesling S; Lobbes MBI; Smidt ML
Ann Surg; 2020 Mar; 271(3):574-580. PubMed ID: 30557203
[TBL] [Abstract][Full Text] [Related]
15. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors of pathologically node-negative disease for HER2 positive and triple-negative breast cancer after neoadjuvant therapy.
Shi Z; Wang X; Qiu P; Liu Y; Zhao T; Sun X; Chen P; Wang C; Zhang Z; Cong B; Wang Y
Gland Surg; 2021 Jan; 10(1):166-174. PubMed ID: 33633973
[TBL] [Abstract][Full Text] [Related]
17. Prediction of axillary pathologic response with breast pathologic complete response after neoadjuvant chemotherapy.
Choi HJ; Ryu JM; Kim I; Nam SJ; Kim SW; Yu J; Lee JE; Lee SK
Breast Cancer Res Treat; 2019 Aug; 176(3):591-596. PubMed ID: 31065874
[TBL] [Abstract][Full Text] [Related]
18. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial.
Boughey JC; McCall LM; Ballman KV; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Flippo-Morton T; Hunt KK
Ann Surg; 2014 Oct; 260(4):608-14; discussion 614-6. PubMed ID: 25203877
[TBL] [Abstract][Full Text] [Related]
19. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.
Koolen BB; Pengel KE; Wesseling J; Vogel WV; Vrancken Peeters MJ; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
Breast; 2013 Oct; 22(5):691-7. PubMed ID: 23414930
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy for triple-negative and Her2 +ve breast cancer: striving for the standard of care.
Roberts A; Hallet J; Nguyen L; Coburn N; Wright FC; Gandhi S; Jerzak K; Eisen A; Look Hong NJ
Breast Cancer Res Treat; 2024 Apr; ():. PubMed ID: 38676808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]